The Global EYLEA Drug Market Is Driven By Rising Prevalence Of Back-Of-The-Eye Diseases
The Global EYLEA drug market primarily includes anti-VEGF drugs used in the treatment of retinal diseases such as age-related macular degeneration (AMD), macular edema following retinal vein occlusion (RVO), diabetic macular edema (DME), and diabetic retinopathy (DR). EYLEA, developed by Regeneron Pharmaceuticals and Bayer, is a human monoclonal antibody designed for intravitreal administration...
0 Commenti
0 condivisioni